Felix Müller, MD, is leading the research project on hallucinogenic and entactogenic drugs. He has years of experience in conducting studies on the effects of MDMA and LSD and has published multiple articles in this field. Currently, he is principal investigator and sponsor of the trials LSD Treatment for Persons With Alcohol Use Disorder (NCT05474989) and The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training (NCT05570708)

Background: Studied medicine, philosophy, logic, and theory of science at Ludwig-Maximilians-University Munich and graduated in medicine and philosophy in 2012. After obtaining his doctoral degree from Technical University Munich he joined the Department of Psychiatry as a resident and study physician in 2013. Since 2018 he is lecturer at the University of Basel. Since 2020, he has been the senior physician in charge for psychedelic-assisted therapy. He has received the Swiss Addiction Research Award (SARA) 2019, the Inger Salling Award 2020, and the Prix Frutiger 2022. He is co-president of the Swiss Medical Society for Psycholytic Therapy (SÄPT)